ST-segment Elevation Myocardial Infarction (STEMI) Clinical Trial
Official title:
Assessment of Anti-Coagulation Therapy on Patient With Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction
Left ventricular thrombus (LVT) is a commom complication after ST segment elevation myocardial infarction (STEMI), reperfusion therapy have reduced the incidence of LVT, however, about 6% of all STEMI patients will develop LVT. the risk of LVT development in anterior STEMI with reduced LVEF are as high as 20%. Although current guideline recommend anti-coagulation therapy, but the evidence still based on observational data, there has been inconsistency with the benefit of the coagulation therapy, give the significant increased bleeding risk by superimpose anti-coagulation therapy to the dual anti-platelet therapy. especially in the era of more potent anti-platelet P2Y12 inhibitor widely used clinical. the mechanism of LVT is different from that of the atrial fibrillation in which the risk of systemic embolism is persistent, coagulation bring absolute clinical benefit for high risk patients. however, for LVT developed following STEMI tend to be temporary, majority of thrombus resolve within 1-3 months after STEMI event. more likely a reflection of coagulation system in response to the necrosis of infarct myocardium. The optimal management in LVT after STEMI warrants further exploration. the desiring of randomized controlled clinical trial to compare dual anti platelet + anti-coagulation and dual anti-platelet without anti-coagulation in patient LVT are justified. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04962178 -
Evaluate Early Invasive Strategy for Patients With STEMI Presenting 24-48 Hours From Symptom Onset
|
N/A | |
| Not yet recruiting |
NCT04549766 -
Predictive Value of PRECISE DAPT Score in STEMI Patients After Primary PCI
|
||
| Not yet recruiting |
NCT05511831 -
The Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI
|
Phase 4 | |
| Completed |
NCT05649696 -
Prolonged Clinical Follow-up of OPTIMA-5
|
Phase 4 | |
| Recruiting |
NCT05506449 -
The RECOVER IV Trial
|
N/A | |
| Completed |
NCT01144819 -
Platelet Inhibition in the Acute Phase of STEMI
|
N/A | |
| Recruiting |
NCT03539133 -
Systemic Organ Communication in STEMI
|
||
| Completed |
NCT01642667 -
Pharmacoinvasive Therapy With Prourokinase
|
Phase 2/Phase 3 | |
| Completed |
NCT04131816 -
HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program
|
N/A | |
| Recruiting |
NCT03768453 -
EARLY-MYO-CMR Registry
|
||
| Completed |
NCT04942977 -
Rehabilitation After Acute Coronary Syndrome: a New Telemonitoring Strategy
|
N/A | |
| Recruiting |
NCT04912518 -
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
|
N/A | |
| Completed |
NCT04996901 -
The Chinese STEMI PPCI Registry (CSPR)
|
||
| Completed |
NCT02197117 -
Effect of Remote Ischemic Conditioning in Heart Attack Patients
|
N/A | |
| Completed |
NCT02733341 -
The Effect of IV Cangrelor and Oral Ticagrelor Study
|
Phase 4 | |
| Not yet recruiting |
NCT04110691 -
Impact of Stent Length and Diameter on Patients Undergoing Primary PCI
|
||
| Recruiting |
NCT05510661 -
Use of Export in Primary Percutaneous Coronary Intervention
|
N/A | |
| Recruiting |
NCT05709626 -
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
|
Phase 4 | |
| Recruiting |
NCT05046483 -
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
|
||
| Active, not recruiting |
NCT04828681 -
Angio-IMR and Cardiac MR-derived MVO in STEMI Patients
|